UCB S.A.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a UCBJY research report →
About the company
UCB S. A. is a biopharmaceutical enterprise dedicated to developing innovative treatments and solutions for individuals living with neurological and immunological diseases.
- CEO
- Jean-Christophe Tellier
- IPO
- 2012
- Employees
- 9,052
- HQ
- Brussels, BE
Price Chart
- Market Cap
- $57.65B
- P/E
- 31.65
- P/S
- 6.38
- P/B
- 4.54
- EV/EBITDA
- 27.55
- Div Yield
- 0.56%
- Gross Margin
- 74.29%
- Op Margin
- 25.32%
- Net Margin
- 20.13%
- ROE
- 15.16%
- ROIC
- 12.13%
- Revenue
- $7.44B · 20.86%
- Net Income
- $1.50B · 40.52%
- EPS
- $3.93 · 39.86%
- Op Income
- $1.12B
- FCF YoY
- 96.49%
- 52W High
- $168.76
- 52W Low
- $98.24
- 50D MA
- $143.02
- 200D MA
- $144.05
- Beta
- 0.20
- Avg Volume
- 39.40K
Get TickerSpark's AI analysis on UCBJY
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our UCBJY coverage
Recent articles, reports, and earnings notes.
No research on UCBJY yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate UCBJY report →Similar companies
Peers in the same neighborhood.